[ad_1]
Sacituzumab govitecan is the first ADC approved for upfront metastatic triple-negative breast cancer regardless of PD-L1 inhibitor eligibility.
Medscape Medical News
[ad_2]
Source link : https://www.medscape.com/viewarticle/sacituzumab-govitecan-gains-first-line-tnbc-indications-2026a1000lod?src=rss
Author :
Publish date : 2026-06-25 16:29:00
Copyright for syndicated content belongs to the linked Source.